Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
about
Risk based neoadjuvant chemotherapy in muscle invasive bladder cancerCytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Outcome of urinary bladder cancer after combined therapiesSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: Case report and literature review.Bladder cancerA phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urotheliumA phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial.Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen.Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin).A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese UrothelSurvival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin TreatmentA phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicityChemotherapy and management of bladder tumours.Systemic Therapy for Invasive Bladder Cancer.Progress in the management of metastatic bladder cancer.Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.Recent advances in bladder cancer chemotherapy.Oral piritrexim, an effective treatment for metastatic urothelial cancerMelphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.Follow-up surveillance strategies for genitourinary malignancies.Management of renal collecting duct carcinoma: a systematic review and the McMaster experience.Upregulation of TRAG3 gene in urothelial carcinoma of the bladder.Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.
P2860
Q26773664-505C771E-D127-4ADB-A74D-8DC0D7C1D056Q27026717-752F48F2-93EB-4614-BFF4-6BC5DCA864E8Q28076180-02DBBC20-3361-41BC-8337-38BB45B7B920Q30240816-A4E9D04E-EEC3-40C0-9DE7-AA2C63188195Q30560260-04B9B474-9610-4254-8381-CBBCAF789CE4Q31976406-E97B81B2-BF62-4746-BAF7-7323D37AB488Q33287243-2881FFB1-B54C-4D8F-8924-CEB9A34B3D43Q33330195-ACE79473-2A45-4FBC-98B6-ECF96980788FQ33340282-CABA7CAA-6638-45B2-9968-16C18B02631BQ33341273-339D7340-F1DB-450D-87D8-72EF65CDA13FQ33342405-81278D62-FBBC-4FC2-B0AC-B0E19690C12AQ33344322-21386C9E-7533-47D2-AFB1-EC1DF0FDDE39Q33361999-F2CEC832-3128-404D-8DBE-9BFED1682EC9Q33364779-16DF5C54-AF12-46BC-9B8E-7DD19444F5B6Q33394158-F698AFB9-B113-43E0-900C-2C9F982C4F94Q33394213-18B13ED3-E549-41FD-91BC-4BFE72D34C84Q33394627-7B1E0B81-EB7F-4C5F-ABCA-84E4F4ED5A4BQ33396202-356F92ED-17B6-44E7-A861-5247A7909E76Q33396809-1B45B798-825E-4A07-93AA-F332BB28A7BEQ33399928-05424AF0-A8C8-4EDD-A37D-7FC9C66E21D6Q33496307-BCD3DA18-3EE8-4095-8163-79A85E9837F0Q33497225-221B662A-BC0E-40A0-A20C-083F032FD0E6Q33503299-AA4D0E03-2399-4FE1-B4FC-038B879285C7Q33503891-C6E880AC-1FEC-4863-B7F1-C206BCE0194BQ33614498-FB15AA03-6E41-48F8-8EDC-672AE07B43B9Q33619249-6B5AB498-B053-4CB3-88AA-651AA0E262F1Q33621281-88A87AFD-002E-47A3-9AE7-F8110446EA6EQ33638615-73F4E796-663F-40DF-BC96-F2E687DC586FQ33729078-9EF2F4F1-54DA-418B-B8BA-5BA846B645A6Q33874502-4AB5C9EF-B09F-44FB-989C-DB7BC167719DQ33891551-E6AA5576-C703-48A4-8917-03DC571D8F69Q33968726-106A6777-740F-4164-A77E-80D66AE93A08Q34206376-8E0C04B6-5FB0-438D-A6E7-BF05F9108D70Q34211041-3ECA11FC-17AC-4AF0-B3B7-4C7DF8BD22DFQ34360273-79CCD1F6-855F-4253-999D-F98BB3FDC0B4Q34511534-2997CD61-A9F2-4384-9240-67981F25AEE8Q34736606-4AA824C6-339D-4E74-8E9B-B21FA8882928Q34758090-37D09241-F0AB-4D8D-A9C4-59F0B192D38FQ34861259-1A95DB5E-5BD5-4E97-AD95-D08957CEBC39Q35076309-8391562C-C8E5-422F-9F52-963E785A208A
P2860
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Methotrexate, vinblastine, dox ...... terns of response and relapse.
@en
Methotrexate, vinblastine, dox ...... terns of response and relapse.
@nl
type
label
Methotrexate, vinblastine, dox ...... terns of response and relapse.
@en
Methotrexate, vinblastine, dox ...... terns of response and relapse.
@nl
prefLabel
Methotrexate, vinblastine, dox ...... terns of response and relapse.
@en
Methotrexate, vinblastine, dox ...... terns of response and relapse.
@nl
P2093
P1433
P1476
Methotrexate, vinblastine, dox ...... terns of response and relapse.
@en
P2093
Sternberg CN
Vaughan ED
P304
P356
10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7
P407
P577
1989-12-01T00:00:00Z